作　　者： (张素琴）; (陈盛阳）; (黄剑辉）; ;

机构地区： 深圳大学

出　　处： 《韶关学院学报》 2020年第9期45-47,共3页

摘　　要： 为评价PEG-rhG-CSF预防恶性浆膜腔内化疗后中性粒细胞减少的可行性、安全性.选择合并恶性浆膜腔积液的恶性肿瘤患者126例实施PEG-rhG-CSF皮下注射的单臂实验研究.结果显示:患者中无因为发生ANC减少而导致死亡发生,未见严重的血小板、肝脏、肾脏毒性反应.可见浆膜腔内化疗后给予PEG-rhG-CSF皮下注射可以很好的预防中性粒细胞减少,具有明确的治疗疗效,临床安全性稳定. To evaluate the feasibility and safety of PEG-rhG-CSF in preventing neutropenia after malignant serosal cavity chemotherapy,one-arm experiment was carried out in 126 patients with malignant tumor complicated with serosal fluid.The results indicate as follow:none of the patients died as a result of the ANC reduction;no serious platelet,liver or renal toxicity was observed.Therefore,subcutaneous injection of PEG-RHG-CSF after serosal cavity chemotherapy can effectively prevent neutropenia,with definite therapeutic effect and stable clinical safety.

关 键 词： 恶性浆膜腔积液 化疗 预防性治疗

领　　域： [医药卫生—肿瘤] [医药卫生—临床医学]